Pharmacological profile of MDL 26,024GO: a novel antiasthmatic agent.
MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.
Baugh
L
L
Merrel Dow Research Institute, Cincinnati, OH.
Abraham
W
W
Matthews
E
E
Lahr
P
P
D000818:Animals; D000941:Antigens / Q000276:immunology; D001200:Ascaris / Q000276:immunology; D001249:Asthma / Q000188:drug therapy*; D001986:Bronchial Spasm / Q000517:prevention & control; D001993:Bronchodilator Agents / Q000627:therapeutic use; D008252:Macaca fascicularis; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D011804:Quinolines; D012018:Reflex / Q000187:drug effects; D012137:Respiratory System / Q000187:drug effects; D012756:Sheep; D013777:Tetrazoles; D013997:Time Factors
D000941:Antigens; D001993:Bronchodilator Agents; D011804:Quinolines; D013777:Tetrazoles; C061326:tetrazolast